Clinical trial
Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.
NCT01276054
Study timeline
Study start (unknown)2010-12-01Date precision: month
Registry last updated2014-08-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Lymphedemaunresolved
Recurrent Breast Cancerunresolved
Stage IA Breast Cancerunresolved
Stage IB Breast Cancerunresolved
Stage II Breast Cancerunresolved
Interventions
technetium Tc 99m sulfur colloidRADIATION
methylene blueDRUG · verified · RxNorm: methylene blue
sentinel lymph node biopsyPROCEDURE
axillary lymph node biopsyPROCEDURE
bioimpedance spectroscopyPROCEDURE
quality-of-life assessmentPROCEDURE
Sponsors & collaborators
University of Southern Californialead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01276054 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.